Roivant Sciences Director Receives Annual Equity Grants
Roivant Sciences Ltd.
Subscribe to track ROIV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Roivant Sciences Ltd. ($ROIV) — Form 4 Filing Alert
Insider: James C. Momtazee (Director) Transaction Date: September 16, 2026 Type: Grant / Award (Code A) Security: Common Shares (RSUs) & Stock Options Shares/Units Awarded: 5,054 RSUs ($0) + 10,531 Options (Exercise: $39.57) Post-Transaction Holdings: 111,959 Common Shares Significance: Low (Routine Annual Director Compensation)
Comprehensive Analysis
Overview & Context
On September 18, 2026, Roivant Sciences Ltd. ($ROIV) filed a Form 4 disclosing that Director James C. Momtazee received annual equity incentive awards on September 16, 2026, pursuant to the Company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy.
Transaction Summary
- Non-Derivative Securities: Awarded 5,054 restricted stock units (RSUs) of Common Shares at $0.00 per share. Following this grant, Mr. Momtazee directly holds 111,959 Common Shares.
- Derivative Securities: Awarded stock options to purchase 10,531 Common Shares with an exercise price of $39.57 per share, expiring September 15, 2036.
- Vesting Terms: Both the RSUs and stock options are scheduled to vest 100% on September 16, 2027, contingent upon continued board service.
Market & Governance Significance
This transaction represents standard, scheduled non-employee director compensation rather than open-market buying or selling activity. As a result, its trading significance is Low.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.